Tilman Todenhöfer, MD

Department of Urology, Eberhard Karls University, Tuebingen, Germany

Tilman Todenhöfer is a urologist with a focus on the management of advanced genitourinary malignancies including prostate and bladder cancer. He has obtained his MD at the university of Freibug Germany. He has been trained as resident at the Eberhard-Karls-University Tuebingen (Chair: Prof. A. Stenzl). Under the supervision of Peter Black and Kim Chi, he worked as postdoctoral research fellow at the Vancouver Prostate Centre, Vancouver, Canada. From 2017 to 2019 he was faculty member at the Dept. of Urology and the lead of the clinical trial unit of the department. In 2019, he was appointed associate Professor of Urology at the Eberhard-Karls-University Tuebingen (apl. Professor). In 2019 he has joined the clinical trial unit "Studienpraxis Urologie“ as principal investigator and co-head of the clinical trial unit.

Tilman Todenhöfer has published over 130 peer reviewed publications. He is a member of various national and international urological associations and research networks and reviewer of various journals including Lancet European Urology, the Journal of Urology, Lancet Oncology Urologic Oncology, Nature Reviews Urology, International Journal of Urology, BMC cancer. He is member of the editorial board of Disease Markers. His major research interests are biomarkers in advanced bladder and prostate cancer, circulating biomarker and bone metastases. He has been awarded numerous prestigious awards including the Maximlian Nitze Award, the Alken Award, the Research award of the Canadian Urologic Association (CUA) and the John Blandy Prize of the British Association of Urological Surgeons.